Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2024-02-20 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
SC TO-T/A Filing
Regulatory Filings
2024-02-20 English
AstraZeneca completes acquisition of Icosavax
Delisting Announcement Classification · 1% confidence The document begins with 'RNS Number : 6559D' and is dated 19 February 2024. It announces the 'Acquisition of Icosavax Completed' by AstraZeneca. This type of announcement, detailing a significant corporate event (M&A completion) and regulatory filing details (RNS number, LSE/Nasdaq context), is characteristic of a general regulatory news service release. Since the document is not a full financial report (like 10-K or IR) but a specific corporate action announcement distributed via the RNS system, it fits best under the general 'Regulatory Filings' category, which serves as a fallback for specific corporate news releases not covered by other codes (like DIV, CAP, or MANG). While it relates to M&A (TAR), TAR is usually for proposals or bids. This is the final completion announcement distributed via RNS, making RNS the most appropriate general classification for this type of market-sensitive news release.
2024-02-19 English
Tagrisso plus chemo approved in US for lung cancer
Legal Proceedings Report Classification · 1% confidence The document is identified by the header 'RNS Number : 5215D' and contains a press release dated '19 February 2024' announcing a regulatory approval (FDA approval in the US) for a drug (Tagrisso). The text is a detailed announcement of clinical trial results (FLAURA2) and their impact, which is characteristic of a major corporate news release. Since it is a formal announcement distributed via RNS (the news service of the London Stock Exchange) and contains significant corporate/product news that doesn't fit the specific categories like Earnings Release (ER) or Capital Update (CAP), it falls best under the general 'Regulatory Filings' category, which serves as a fallback for official regulatory news distributed via these channels, or potentially an Earnings Release if it were quarterly results, but this is a specific drug approval announcement. Given the context of RNS distribution and the nature of the announcement (FDA approval based on trial data), 'RNS' (Regulatory Filings) is the most appropriate general classification for this type of market-sensitive news release not covered by other specific codes.
2024-02-19 English
FDA accepts Dato-DXd BLA for nonsquamous NSCLC
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 5214D' and is dated February 19, 2024. It details a significant corporate event: the acceptance of a Biologics License Application (BLA) by the FDA for a drug developed by AstraZeneca and Daiichi Sankyo. The text concludes with standard boilerplate language referencing RNS, the London Stock Exchange, and the Financial Conduct Authority (FCA). This structure is characteristic of a general regulatory news announcement disseminated via the RNS system, rather than a comprehensive report (like 10-K or IR) or a specific announcement like a dividend (DIV) or director dealing (DIRS). Since it is a general regulatory announcement that doesn't fit the more specific categories (like ER, CT, or CAP), the most appropriate classification is the general regulatory filing category.
2024-02-19 English
Tagrisso improved PFS in Stage III lung cancer
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 5213D' and is dated February 19, 2024. It details positive clinical trial results (LAURA Phase III) for a drug (Tagrisso) and concludes with standard boilerplate text referencing RNS, the London Stock Exchange, and the Financial Conduct Authority. This structure is characteristic of a regulatory news service announcement, which is often used for material non-public information dissemination. Since the content is a specific announcement of clinical trial results rather than a full financial report (10-K, IR) or a general management/governance update, the most appropriate classification is the general regulatory announcement category, RNS, as it is explicitly branded as an RNS release.
2024-02-19 English
SC TO-T/A Filing
Regulatory Filings
2024-02-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.